Shares of Tesaro (TSRO), an oncology-focused biopharma company, skyrocketed after the news that it has been working with advisors for a possible sale. The stock, which opened at $26.46 today, reached a maximum of $38.35 and jumped more than 30%. Because of the sudden spike, the trading of Tesaro shares was halted.
After Bloomberg reported that the company has been working with advisors for a possible sale, the stock skyrocketed and settled at $34.96 when the market closed on Friday. Last week on the same day, the stock plunged 19% after it released initial data from the Phase 1 AMBER study, which disappointed the investors.
Arena Pharmaceuticals soars on the $1.2 billion deal with United Therapeutics
Following the buyout report, Tesaro’s rival Clovis Oncology (CLVS) also increased and was up 8.48% at $16.75 when the market closed today.
On Tuesday, pharma giants AstraZeneca and Merck (MRK) announced that FDA will review their regulatory application with priority for the label expansion of its cancer treatment therapy. Encouraged by this announcement, Tesaro’s shares, which has got a cancer drug named Zejula, rose 8%.
When the company reported Q3 financial results two weeks ago, its earnings surpassed consensus views, while revenue missed the estimates. Tesaro posted a loss of $2.49 per share on revenues of $64.4 million.
TSRO stock has dropped 58% in the year-to-date period and 60% in the past 52 weeks. Shares of the Waltham, Massachusetts-based company hit a 52-week low of ($23.41) last Friday and the yearly high ($89.72) on November 16, 2017.
We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips
Most Popular
Charles Schwab (SCHW) Q1 2024 Earnings: Key financials and quarterly highlights
The Charles Schwab Corporation (NYSE: SCHW) reported first quarter 2024 earnings results today. Net revenues decreased 7% year-over-year to $4.74 billion. Net income available to common shareholders was $1.25 billion,
GS Earnings: All you need to know about Goldman Sachs’ Q1 2024 earnings results
The Goldman Sachs Group, Inc. (NYSE: GS) reported its first quarter 2024 earnings results today. Net revenues were $14.21 billion, up 16% from the same period last year. Net earnings
Centuri Holdings takes the IPO route to expand. Here’s all you need to know
Utility infrastructure service provider Centuri Holdings, Inc. has initiated an initial public offering as it seeks to spin off from parent company Southwest Gas Holdings and become an independent entity.
